AbbVie ABBV
NYSE ABBV
$266.50 +2.16 (+0.82%)
As of: Sep 28, 2026 · 3:59 PM EDT

AbbVie (ABBV) Gains from Sales and Divestitures (2022)

Updated

AbbVie's Gains from Sales and Divestitures was $172 million in FY2022, up 152.9% from $68 million in FY2021.

Analysis

AbbVie (ABBV) Gains from Sales and Divestitures (2022) Analysis & Trends

  • Gains from Sales and Divestitures shows a three-year compound annual growth rate of -19.5% (FY2019 to FY2022).
  • The FY2022 figure marks the highest annual Gains from Sales and Divestitures since FY2019.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was $68 million in FY2021 and $330 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 653.54 Bn 572.07 Bn 17.26 Bn
2 AbbVie 467.01 Bn 440.17 Bn 12.70 Bn
3 Merck 367.16 Bn 321.59 Bn 12.21 Bn
4 Novartis Ag 277.56 Bn 233.43 Bn 11.24 Bn
5 Astrazeneca 258.23 Bn 231.79 Bn 12.86 Bn
6 Amgen 224.14 Bn 179.54 Bn 7.24 Bn
7 Gilead Sciences 187.30 Bn 161.42 Bn 6.22 Bn
8 Pfizer 163.47 Bn 110.41 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.31 Bn 105.31 Bn 2.84 Bn
10 Bristol Myers Squibb 128.45 Bn 79.72 Bn 9.25 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 172.00 Mn
API Access

AbbVie Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ABBV&period=max&api_key=YOUR_API_KEY